The SUSTAIN 7 clinical trial compared the effectiveness of once-weekly semaglutide (0.5 mg or 1 mg) with once-weekly dulaglutide (0.75 mg or 1.5 mg) in type 2 diabetes patients over 40 weeks
GLA khi vo c th s chuyn ha thnh DGLA c tc dng gim cc triu chng vim trong khi CLA c th gim khi lng cht bo

Compensation for medical costs encompasses both past expenses and projected future treatment needs including ongoing medical treatment: Hospital stays and emergency care: Costs for urgent treatment of gastroparesis symptoms, intestinal blockages requiring emergency intervention, or surgical procedures to remove portions of damaged intestines Diagnostic testing: Expenses for gastric emptying studies, endoscopic examinations, imaging scans, and vision assessments necessary to diagnose and monitor conditions Ongoing treatment and medications: Long-term costs for prescription drugs managing symptoms, nutritional supplementation for malabsorption issues, and regular medical monitoring Surgical interventions: Bills for gallbladder removal, intestinal blockage repair, feeding tube placement, or other procedures addressing complications Future medical care: Projected lifetime costs for conditions with no cure, including NAION vision loss requiring ongoing ophthalmologic care and gastroparesis demanding permanent dietary modifications Courts require detailed medical records, itemized billing statements, and expert testimony projecting future care needs

Older GLP-1 medications show minimal risk Liraglutide, dulaglutide, and exenatide did not show statistically significant increases in hair loss reports
Clinical studies indicate that losing just 5% to 10% of body weight produces measurable improvements in arthritis pain and mobility, with continued gains at 15% to 20% weight loss